Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common Stock

WALTHAM, Mass., Nov. 18, 2024 /PRNewswire/ -- Spyre Therapeutics, Inc. ("Spyre" or the "Company") (NASDAQ: SYRE), a clinical-stage biotechnology company utilizing best-in-class antibody engineering, rational therapeutic combinations, and precision medicine approaches to target improved efficacy and convenience in the treatment of inflammatory bowel disease ("IBD"), today announced the pricing of its previously announced underwritten public offering of 7,275,000 shares of its common stock at a price to the p ...